Sarah Fredriksson, PhD, Chairman of the Board
PhD and M.Sc. from Lund University, Sweden. CEO of AQILION AB. Fredriksson has a background as founder and CEO of Genovis AB (listed on First North, Nasdaq OMX Nordic) and most recently CEO of Edvince AB. Currently she serves as board member of LU Holding, Edvince AB, Respiratorius AB and SwedenBIO. Former board member of AcuCort AB.
Niklas Arnberg, PhD, Director of the Board
Professor, Dept. of Virology, Inst. of Clinical Microbiology, Umeå University, Sweden. Discovered that sialic acid is the receptor for certain adenoviruses and defended his doctorial thesis in this subject in 2001. Arnberg has continued his research within this field and is one of the founders of Adenovir Pharma AB
Clas Runnberg, Director of the Board
Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, in the US and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, advisor to the EIT Health program and a board member of Monivent AB. Former chairman of P.U.L.S. AB (today known as AQILION AB).
Göran Wadell, MD, PhD, Deputy Director of the Board
Professor, Dept. of Virology, Umeå University, Sweden. Wadell is a recognized scientist in the field of adenovirus and one of the founders of Adenovir Pharma AB.